ArticleFrontiers in nephrology2026
Accuracy of valganciclovir dosing following kidney transplantation and its impact on clinical outcomes.
Article in Frontiers in nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Valganciclovir is widely used as prophylaxis against cytomegalovirus (CMV) infection following solid organ transplantation. However, valganciclovir requires dose adjustment based on kidney function. This retrospective observational study at a London kidney transplant center explored the accuracy of valganciclovir dosing in the first 3 months following transplantation and its impact on clinical outcomes. Data for adult kidney transplant recipients (KTRs) receiving valgancivloir prophylaxis between 2017 to 2019 was analyzed. The primary outcome was the difference between the prescribed and optimum valganciclovir dose (calculated by creatinine clearance) on days 10-92 after surgery. Secondary outcomes included associations between valganciclovir dosing with CMV DNAemia, cytopenias and rejection. For the 90 KTRs included, the valganciclovir dose was optimum for 51%, underdosed for 31% and overdosed for 18% of the study period. Significant associations were shown for underdosing and CMV DNAemia (B = 2.88, SE = 1.14, p=0.01, 95% CI [1.90,166.1]) as well as overdosing and neutropenia (B = 2.29, SE 0.99, p=0.02, 95% CI [1.42,68.71]). This study highlights the difficulty in optimally dosing valganciclovir in KTRs post-operatively and importantly shows significant associations between suboptimal dosing and clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.